CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗中的 T 细胞耗竭及克服策略
英文原题：T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
查看英文原题
T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤免疫疗法已在临床实践中取得良好疗效，受到越来越多关注。细胞毒性T细胞无疑在肿瘤免疫治疗中发挥重要作用。作为一种革命性的肿瘤免疫疗法，CAR-T 细胞疗法在血液系统癌症治疗中取得突破。然而，T细胞在体内易发生耗竭，尤其是在进入实体瘤后。T细胞耗竭可能导致CAR-T 治疗实体瘤效果不佳。本文综述T细胞耗竭的原因及其发生发展过程，并讨论如何通过调节T细胞耗竭改善CAR-T 疗效。
展开英文摘要原文
Tumour immunotherapy has achieved good therapeutic effects in clinical practice and has received increased attention. Cytotoxic T cells undoubtedly play an important role in tumour immunotherapy. As a revolutionary tumour immunotherapy approach, chimeric antigen receptor T-cell (CAR-T-cell) therapy has made breakthroughs in the treatment of haematological cancers.
However, T cells are easily exhausted in vivo, especially after they enter solid tumours. The exhaustion of T cells can lead to poor results of CAR-T-cell therapy in the treatment of solid tumours.
Here, we review the reasons for T-cell exhaustion and how T-cell exhaustion develops.
We also review and discuss ways to improve CAR-T-cell therapy effects by regulating T-cell exhaustion.
论文信息
- 作者
- Yin X、He L、Guo Z
- 单位
- Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, 210023, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Immunology2023 Aug
- 原文标识
- PubMed 36942414 · DOI 10.1111/imm.13642